Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CCR1 | P32246 | 3/20 | 0.46 |
| ▸ | CCR5 | P51681 | 3/20 | 0.46 |
| ▸ | CCR8 | P51685 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625981 | 0.87 | GRM5 (0.48) | CYP2A6KDM4EGRM5TSHRHTT | |
| SCHEMBL2462770 | 0.86 | CYP2A6 (0.67) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL3660432 | 0.86 | GRM5 (0.48) | CYP2A6KDM4ELMNACYP1A2GRM5 | |
| Hydrochloric Acid SCHEMBL6004892 | 0.84 | CYP2A6 (0.64) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL10031169 | 0.82 | CYP2A6 (0.62) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL29327575 | 0.82 | CYP2A6 (0.43) | CYP2A6KDM4EGRM5TP53NPC1 | |
| SCHEMBL9958124 | 0.80 | KDM4E (0.54) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL31252166 | 0.80 | KDM4E (0.54) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL9958239 | 0.80 | KDM4E (0.54) | CYP2A6KDM4ELMNACCR1CCR5 | |
| SCHEMBL4179017 | 0.80 | GRM5 (0.71) | KDM4ELMNAGRM5TP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4074376-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | Nippon Shinyaku Co., Ltd. (JP) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021117846-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | 日本新薬株式会社 | 2021-06-17 | — | — | WO | disclosed |
| US-20120095011-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20090131463-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | disclosed |
| CN-1589277-A | 6-O-carbamate-11,12-lacto-ketolide antimicrobials | ORTHO MCNEIL PHARM INC (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1430068-A1 | 6-O-CARBAMATE-11,12-LACTO-KETOLIDE ANTIMICROBIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6713455-B2 | A BICYCLIC HETEROAROMATIC COMPOUND CONTAINING TWO KETO, TWO ESTER, A CARBAMATE GROUPS AND A METHYL, HYDROXY AND AMINE SUBSTITUTED OXYPYRAN RING; USEFUL ANTIBACTERIAL AGENT FOR TREATING PNEUMONIA, SKIN, SOFT TISSUE AND BONE INFECTIONS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030125267-A1 | 6-O-carbamate-11,12-lacto-ketolide antimicrobials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003024986-A1 | 6-O-CARBAMATE-11,12-LACTO-KETOLIDE ANTIMICROBIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125267-A1 | 6-O-carbamate-11,12-lacto-ketolide antimicrobials | ARG1, LPO, Q6ZSR9 | CYP2A6 601/4885KDM4E 39/4885LMNA 3417/4885 |
| US-20090131463-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | CYP2A6 138/4885KDM4E 1501/4885LMNA 3223/4885 |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | CYP2A6 3817/4885KDM4E 713/4885LMNA 3159/4885 |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | PDGFRB, PDGFRA, PDGFA | CYP2A6 3529/4885KDM4E 1993/4885LMNA 3787/4885 |
| US-20120095011-A1 | NOVEL COMPOUNDS | C1R, TBXA2R, F12 | CYP2A6 138/4885KDM4E 1501/4885LMNA 3223/4885 |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | CYP2A6 2421/4885KDM4E 3536/4885LMNA 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.